Do Early Luteal Serum Progesterone Levels Predict the Reproductive Outcomes in IVF with Oral Dydrogesterone for Luteal Phase Support?

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Jul 31

PMID 31361764

Citations 6

Authors

Antoine Netter

Julien Mancini

Christophe Buffat

Aubert Agostini

Jeanne Perrin

Blandine Courbiere

Affiliations

Soon will be listed here.

Abstract

Objective: We sought to determine whether the early luteal serum progesterone (P4) level predicts the success of IVF treatment with oral dydrogesterone for luteal support.

Method: This retrospective monocentric cohort study included 242 women who underwent IVF treatment with fresh embryo transfer (ET) between July 2017 and June 2018. The population was unselected, and women were treated according to our unit's usual stimulation protocols. For the luteal phase support (LPS), all women were supplemented with a 10 mg three-times-daily dose of oral dydrogesterone beginning on the day of oocyte pick-up (OPU). Blood sampling was performed on the day of ET (Day 2-3 after OPU) to determine the early luteal serum progesterone level.

Results: ROC curve analysis allowed us to determine two thresholds for the prediction of live birth using the early P4 level. Women who had early luteal P4 levels greater than 252 nmol/l had a significantly higher live birth rate (27.1%) than women with early luteal P4 between 115 and 252 nmol/l (17.2%) and women with early luteal P4 below 115 nmol/l (6.0%; p = 0.011). After a multiple regression analysis, an early luteal P4 level greater than 252 nmol/l was still associated with a higher chance of a live birth than a P4 between 115 and 252 nmol/l (OR = 0.40 [0.18-0.91]; p = 0.028) or a P4 below 115 nmol/l (OR = 0.10 [0.01-0.52]; p = 0.006).

Conclusions: Our study suggests a positive association between early P4 levels and reproductive outcomes in IVF using oral dydrogesterone for luteal support. The inconsistencies between our results and those of other studies suggest that extrapolation is impractical. Further larger prospective cohort studies should be conducted to determine reliable thresholds that could be used to personalize luteal phase support.

Citing Articles

Progesterone level in assisted reproductive technology: a systematic review and meta-analysis.

Lim Y, Hamdan M, Maheshwari A, Cheong Y Sci Rep. 2024; 14(1):30826.

PMID: 39730597 PMC: 11681007. DOI: 10.1038/s41598-024-81539-z.

Serum progesterone measurement on the day of fresh embryo transfer and its correlation with pregnancy success rates: A prospective analysis.

Dias C, Furlan S, Ferriani R, Navarro P Clinics (Sao Paulo). 2024; 79():100511.

PMID: 39388739 PMC: 11736334. DOI: 10.1016/j.clinsp.2024.100511.

Luteal phase support in assisted reproductive technology.

Garg A, Zielinska A, Yeung A, Abdelmalak R, Chen R, Hossain A Nat Rev Endocrinol. 2023; 20(3):149-167.

PMID: 38110672 DOI: 10.1038/s41574-023-00921-5.

Role of Dydrogesterone for Luteal Phase Support in Assisted Reproduction.

Patki A Reprod Sci. 2023; 31(1):17-29.

PMID: 37488405 DOI: 10.1007/s43032-023-01302-z.

Regulatory T cells are paramount effectors in progesterone regulation of embryo implantation and fetal growth.

Green E, Moldenhauer L, Groome H, Sharkey D, Chin P, Care A JCI Insight. 2023; 8(11).

PMID: 37191999 PMC: 10393240. DOI: 10.1172/jci.insight.162995.

References

Yu S, Long H, Chang H, Liu Y, Gao H, Zhu J . New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018; 33(2):229-237. DOI: 10.1093/humrep/dex367. View

Chakravarty B, Shirazee H, Dam P, Goswami S, Chatterjee R, Ghosh S . Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol. 2005; 97(5):416-20. DOI: 10.1016/j.jsbmb.2005.08.012. View

Patki A, Pawar V . Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecol Endocrinol. 2007; 23 Suppl 1:68-72. DOI: 10.1080/09513590701584857. View

van der Linden M, Buckingham K, Farquhar C, Kremer J, Metwally M . Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015; (7):CD009154. PMC: 6461197. DOI: 10.1002/14651858.CD009154.pub3. View

Tomic V, Tomic J, Klaic D, Kasum M, Kuna K . Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015; 186:49-53. DOI: 10.1016/j.ejogrb.2014.11.002. View

Tournaye H, Sukhikh G, Kahler E, Griesinger G . A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017; 32(5):1019-1027. PMC: 5400051. DOI: 10.1093/humrep/dex023. View

Kushnir V, Barad D, Albertini D, Darmon S, Gleicher N . Systematic review of worldwide trends in assisted reproductive technology 2004-2013. Reprod Biol Endocrinol. 2017; 15(1):6. PMC: 5223447. DOI: 10.1186/s12958-016-0225-2. View

Griesinger G, Tournaye H, Macklon N, Petraglia F, Arck P, Blockeel C . Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online. 2019; 38(2):249-259. DOI: 10.1016/j.rbmo.2018.11.017. View

Yovich J, Conceicao J, Stanger J, Hinchliffe P, Keane K . Mid-luteal serum progesterone concentrations govern implantation rates for cryopreserved embryo transfers conducted under hormone replacement. Reprod Biomed Online. 2015; 31(2):180-91. DOI: 10.1016/j.rbmo.2015.05.005. View

10.

Venetis C, Mol B, Kolibianakis E . Low as well as high serum P4 levels in the early and mid-luteal phase reduce the chance of a live birth following IVF treatment with fresh embryo transfer: where is the evidence?. Hum Reprod. 2018; 33(12):2312-2313. DOI: 10.1093/humrep/dey311. View

11.

Alsbjerg B, Thomsen L, Elbaek H, Laursen R, B Povlsen B, Haahr T . Progesterone levels on pregnancy test day after hormone replacement therapy-cryopreserved embryo transfer cycles and related reproductive outcomes. Reprod Biomed Online. 2018; 37(5):641-647. DOI: 10.1016/j.rbmo.2018.08.022. View

12.

Thomsen L, Kesmodel U, Erb K, Bungum L, Pedersen D, Hauge B . The impact of luteal serum progesterone levels on live birth rates-a prospective study of 602 IVF/ICSI cycles. Hum Reprod. 2018; 33(8):1506-1516. DOI: 10.1093/humrep/dey226. View

13.

Gibbons W, Toner J, HAMACHER P, Kolm P . Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril. 1998; 69(1):96-101. DOI: 10.1016/s0015-0282(97)00457-3. View

14.

Mol B, Bossuyt P, Sunkara S, Garcia Velasco J, Venetis C, Sakkas D . Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients. Fertil Steril. 2018; 109(6):968-979. DOI: 10.1016/j.fertnstert.2018.04.037. View

15.

Labarta E, Mariani G, Holtmann N, Celada P, Remohi J, Bosch E . Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study. Hum Reprod. 2017; 32(12):2437-2442. DOI: 10.1093/humrep/dex316. View

16.

Child T, Leonard S, Evans J, Lass A . Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles. Reprod Biomed Online. 2018; 36(6):630-645. DOI: 10.1016/j.rbmo.2018.02.001. View

17.

Fauser B, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J . Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab. 2002; 87(2):709-15. DOI: 10.1210/jcem.87.2.8197. View

18.

Altman D, Lausen B, Sauerbrei W, Schumacher M . Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994; 86(11):829-35. DOI: 10.1093/jnci/86.11.829. View

19.

Wetendorf M, DeMayo F . The progesterone receptor regulates implantation, decidualization, and glandular development via a complex paracrine signaling network. Mol Cell Endocrinol. 2011; 357(1-2):108-18. PMC: 3443857. DOI: 10.1016/j.mce.2011.10.028. View

20.

Griesinger G, Blockeel C, Tournaye H . Oral dydrogesterone for luteal phase support in fresh in vitro fertilization cycles: a new standard?. Fertil Steril. 2018; 109(5):756-762. DOI: 10.1016/j.fertnstert.2018.03.034. View